Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The EMA has started a review of Leo Pharma’s interleukin-13 ... a category that is currently dominated by Sanofi and Regeneron’s Dupixent. The EU regulator is reviewing tralokinumab for ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Dupixent becomes the first-ever targeted therapy ... The drug is also under review for this use in China, Japan, and other countries worldwide. Sanofi and Regeneron estimate that there are around ...

Dupixent continues to be a transformative medicine ... an additional share repurchase authorization. I'll conclude with a review of our 2025 financial guidance. We expect 2025 R&D spend to be ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.71. Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call ...

Dupixent’s sales rose 16% year over year ... The FDA granted priority review to a supplemental new drug application (sNDA) seeking approval for Merck’s oral HIF-2α inhibitor, Welireg for ...

And we expect to see demand increase from 2026 once payers have completed their review process and put Gepotidacin ... is the exacerbation data competitive with Dupixent and have you shown an ...